General Newsroom Hero 1920x480 (4:1)
Our Work

Latham & Watkins Advises Environmental Impact Acquisition Corp. in SPAC Business Combination With GreenLight Biosciences, Inc.

August 10, 2021
A multidisciplinary team, led from Los Angeles, is advising the SPAC in the transaction that will advance development of breakthrough biomanufacturing platform capable of discovering, developing, scaling, and commercializing ribonucleic acid (RNA) solutions.

GreenLight Biosciences, Inc., a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture, and Environmental Impact Acquisition Corp., a publicly traded special purpose acquisition company, have agreed to a business combination that will result in GreenLight becoming a publicly-listed company.

Latham & Watkins LLP represents Environmental Impact Acquisition Corp. in the transaction with a corporate team led by Los Angeles partners Steven Stokdyk and Brian Duff with associates Joseph Porter, Kenneth Hagan, Grace Garcea, Dylan Towns, Celia Lown, and Molly Wolfe. Advice was also provided on securities matters by Los Angeles partner Brent Epstein, tax matters by Los Angeles partner David Taub and Bay Area partner Katharine Moir with associates Vanessa King and Alan Kimball; on antitrust matters by Washington, D.C. partner Jason Cruise and Washington, D.C. counsels Peter Todaro and Joseph Simei; on environmental matters by Los Angeles counsel Aron Potash with associate Jennifer Garlock; on data privacy matters by Bay Area counsel Robert Blamires with associate Kiara Vaughn; on intellectual property matters by Los Angeles partner Ghaith Mahmood with associate Nicole Nour; and on FDA regulatory matters by Washington, D.C. partner Ben Haas with associate Seth Olson.